EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients



Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients



Thrombosis and Haemostasis 77(2): 298-302



The pharmacokinetics of a second-generation recombinant B-domain deleted factor VIII (FVIII) preparation (r-VIII SQ) were studied in 36 patients with severe hemophilia A. In contrast to full-length recombinant FVIII, no albumin needs to be added to stabilize the final formulation of this B-domain deleted FVIII preparation. The in vivo recovery and half-life of r-VIII SQ were similar to those of plasma-derived (pd) FVIII (mean half-life of r-VIII SQ, 11.7 h).

(PDF emailed within 1 workday: $29.90)

Accession: 009307669

Download citation: RISBibTeXText

PMID: 9157585



Related references

Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. Journal of Thrombosis and Haemostasis 1(11): 2450-2451, 2003

Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII. Journal of Thrombosis and Haemostasis 2(4): 605-611, 2004

Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study. Journal of Korean Medical Science 33(1): E5-E5, 2017

Safety and efficacy of ReFacto, the B domain-deleted recombinant factor VIII , in home therapy of previously treated patients with severe hemophilia A An Italian multicenter trial. Blood 96(11 Part 1): 262a, November 16, 2000

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 18(5): 798-804, 2013

Use of B-domain deleted recombinant factor VIII in the surgical management of patients with hemophilia A. Blood 94(10 SUPPL 1 PART 1): 236a, Nov 15, 1999

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 15(4): 869-880, 2010

A four-year update of safety and efficacy of a second generation B-domain deleted factor VIII in previously untreated hemophilia A patients. Blood 92(10 SUPPL 1 PART 1-2): 555A, Nov 15, 1998

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 9(1): 38-49, 2003

The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A. Journal of Thrombosis and Haemostasis 13(3): 370-379, 2016

The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 11(3): 292-293, 2005

Safety and efficacy of a second generation, B-domain deleted recombinant factor VIII in previously treated patients A four year update. Blood 92(10 SUPPL 1 PART 1-2): 555A, Nov 15, 1998

Recombinant B domain deleted porcine factor VIII for the treatment of bleeding episodes in adults with acquired hemophilia A. Expert Review of Hematology 8(4): 427-432, 2016

Viral safety of B-domain deleted recombinant factor VIII. Seminars in Hematology 38(2 Suppl 4): 32-39, 2001

Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thrombosis and Haemostasis 85(1): 93-100, 2001